Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors

NCT02502708 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT02502708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02502708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2015
Completion date
February 28, 2020
Enrollment
81 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, ependymoma, glioblastoma multiforme, glioma, gliosarcoma, malignant brain tumor, medulloblastoma, primary cns tumor